Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML : Results from the SAL‐MODULE phase I study
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19436 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Christoph Röllig und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: Staurosporine, Gemtuzumab, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Novartis.
Abstract (Originalsprache)
We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3 ‐mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three sequential doses of 3 mg/m 2 GO in combination with ‘7 + 3’ induction were evaluated. Based on safety findings in 12 patients, our results show that 3 mg/m 2 GO on Days 1 + 4 and 100 mg midostaurin on Days 8–21 can be safely combined with IC in newly diagnosed AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Dresden, Germany.
- Department of Medicine A, University Hospital Münster, Münster, Germany.
- Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Department of Internal Medicine V, Nuremberg Hospital North, Paracelsus Medical University, Nuremberg, Germany.
- Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany.
ORCID-Profile: Christoph Röllig, Christoph Schliemann, Leo Ruhnke, Maher Hanoun
Förderung
- Pfizer
- Novartis
Zitieren
APA
Röllig, C., Schliemann, C., Ruhnke, L., Fransecky, L., Heydrich, B. N., Hanoun, M., Noppeney, R., Schäfer-Eckart, K., Wendelin, K., Mikesch, J. H., Middeke, J. M., Reimann, M., Fiebig, F., Zukunft, S., Wermke, M., Serve, H., Platzbecker, U., Müller-Tidow, C., Baldus, C. D., & Bornhäuser, M. (2024). Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML : Results from the SAL‐MODULE phase I study. British Journal of Haematology. https://doi.org/10.1111/bjh.19436
Vancouver
Röllig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, et al. Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML : Results from the SAL‐MODULE phase I study. British Journal of Haematology. 2024. doi:10.1111/bjh.19436
BibTeX
@article{Rllig2024,
author = {Röllig, Christoph and Schliemann, Christoph and Ruhnke, Leo and Fransecky, Lars and Heydrich, Björn-Niklas and Hanoun, Maher and Noppeney, Richard and Schäfer-Eckart, Kerstin and Wendelin, Knut and Mikesch, Jan-Henrik and Middeke, Jan Moritz and Reimann, Manja and Fiebig, Frank and Zukunft, Sven and Wermke, Martin and Serve, Hubert and Platzbecker, Uwe and Müller-Tidow, Carsten and Baldus, Claudia D and Bornhäuser, Martin},
title = {Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML : Results from the SAL‐MODULE phase I study},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19436}
}
EUVIMED